Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-Based Therapy

LESSONS LEARNED: Cabazitaxel has activity in squamous cell carcinoma of the head and neck (SCCHN) and taxane-resistant cell lines. For the first time, cabazitaxel was investigated in incurable patients with recurrent SCCHN. Patients were randomly assigned to cabazitaxel every 3 weeks or weekly metho...

Descripción completa

Detalles Bibliográficos
Autores principales: Machiels, Jean-Pascal, Van Maanen, Aline, Vandenbulcke, Jean-Marie, Filleul, Bertrand, Seront, Emmanuel, Henry, Stéphanie, D’Hondt, Lionel, Lonchay, Christophe, Holbrechts, Stéphane, Boegner, Petra, Brohee, Dany, Dequanter, Didier, Louviaux, Ingrid, Sautois, Brieuc, Whenham, Nicolas, Berchem, Guy, Vanderschueren, Brigitte, Fontaine, Christel, Schmitz, Sandra, Gillain, Aline, Schoonjans, Joelle, Rottey, Sylvie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2016
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5153346/
https://www.ncbi.nlm.nih.gov/pubmed/27903924
http://dx.doi.org/10.1634/theoncologist.2016-0296

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5153346/
https://www.ncbi.nlm.nih.gov/pubmed/27903924
http://dx.doi.org/10.1634/theoncologist.2016-0296

Ejemplares similares